KW 2450

Drug Profile

KW 2450

Alternative Names: KW-2450

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin receptor antagonists; Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Solid tumours

Most Recent Events

  • 17 Apr 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 17 Apr 2013 Discontinued - Phase-I/II for Breast cancer in USA (PO)
  • 24 Jan 2013 KW 2450 is still in Phase-I/II trials for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top